Unknown

Dataset Information

0

Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions.


ABSTRACT: Acute kidney injury (AKI) is a potentially fatal syndrome characterized by a rapid decline in kidney function caused by ischemic or toxic injury to renal tubular cells. The widely used chemotherapy drug cisplatin accumulates preferentially in the renal tubular cells and is a frequent cause of drug-induced AKI. During the development of AKI the quiescent tubular cells reenter the cell cycle. Strategies that block cell-cycle progression ameliorate kidney injury, possibly by averting cell division in the presence of extensive DNA damage. However, the early signaling events that lead to cell-cycle activation during AKI are not known. In the current study, using mouse models of cisplatin nephrotoxicity, we show that the G1/S-regulating cyclin-dependent kinase 4/6 (CDK4/6) pathway is activated in parallel with renal cell-cycle entry but before the development of AKI. Targeted inhibition of CDK4/6 pathway by small-molecule inhibitors palbociclib (PD-0332991) and ribociclib (LEE011) resulted in inhibition of cell-cycle progression, amelioration of kidney injury, and improved overall survival. Of additional significance, these compounds were found to be potent inhibitors of organic cation transporter 2 (OCT2), which contributes to the cellular accumulation of cisplatin and subsequent kidney injury. The unique cell-cycle and OCT2-targeting activities of palbociclib and LEE011, combined with their potential for clinical translation, support their further exploration as therapeutic candidates for prevention of AKI.

SUBMITTER: Pabla N 

PROVIDER: S-EPMC4413320 | BioStudies | 2015-01-01T00:00:00Z

REPOSITORIES: biostudies

Similar Datasets

2015-01-01 | S-EPMC4734632 | BioStudies
2018-01-01 | S-EPMC6058325 | BioStudies
1000-01-01 | S-EPMC5332876 | BioStudies
1000-01-01 | S-EPMC5791060 | BioStudies
2020-01-01 | S-EPMC7221100 | BioStudies
2014-01-01 | S-EPMC3972320 | BioStudies
2016-01-01 | S-EPMC4823749 | BioStudies
2021-01-01 | S-EPMC7803968 | BioStudies
2017-01-01 | S-EPMC5535826 | BioStudies
2020-01-01 | S-EPMC7076185 | BioStudies